BABAM1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population targeting the BABAM1 gene in the A-549 human lung carcinoma cell line. This product provides a heterogeneous pool of gene-disrupted cells, enabling loss-of-function studies in a lung adenocarcinoma context. The polyclonal format is particularly useful for assessing population-level responses to genotoxic stress and therapeutic agents, avoiding clonal selection biases while maintaining the ability to examine DNA repair defects and drug sensitivity. The targeting strategy harnesses CRISPR/Cas9-mediated genome editing to disrupt BABAM1 expression, creating a robust model for investigating BRCA1-A complex biology and homologous recombination repair.
The A-549 cell line, derived from a human lung adenocarcinoma, is an epithelial model extensively employed in cancer biology and pharmacological research. These cells retain key features of alveolar epithelial origin and are widely used to study mechanisms of chemoresistance, DNA damage response, and tumor suppressor pathways. Their adherent growth and compatibility with standard transfection and imaging protocols make them an ideal host for generating gene-edited polyclonal populations. This knockout model builds upon the well-characterized A-549 background to dissect the contribution of BABAM1 to genomic stability and therapeutic vulnerability.
BABAM1 (also known as MERIT40) functions as a scaffold subunit within the BRCA1-A complex, which is rapidly recruited to DNA double-strand breaks (DSBs) through its affinity for Lys-63-linked ubiquitin chains on histone H2A/H2AX. This ubiquitin landscape is established by the sequential action of ATM kinase, MDC1, RNF8, and RNF168 following DSB formation. The BRCA1-A complex, containing ABRAXAS1, BRCC36, BRE, and BABAM2, docks onto these ubiquitinated histones, enabling the subsequent accumulation of BRCA1 and RAD51 to promote homologous recombination repair. BABAM1 thus plays a central role in connecting upstream DNA damage signals to downstream repair effectors, maintaining genomic integrity under replication stress and ionizing radiation.
In the A-549 lung adenocarcinoma context, disrupting BABAM1 compromises the BRCA1-A-dependent repair cascade, potentially leading to persistent DNA damage and increased reliance on alternative repair pathways. This is particularly relevant for understanding chemoresistance mechanisms observed in non-small cell lung cancer, where DNA repair proficiency often limits the efficacy of platinum-based agents and PARP inhibitors. The BABAM1 knockout model enables researchers to explore how deficiency of this scaffold protein alters sensitivity to genotoxic insult and might reveal synthetic lethal interactions that can be exploited therapeutically.
These polyclonal knockout cells are suited for a broad range of experimental applications. Western blotting confirms BABAM1 protein loss, while immunofluorescence detection of ??H2AX foci quantifies DSB accumulation. Comet assays measure DNA strand breakage directly, and colony formation assays with cisplatin or PARP inhibitors like olaparib assess clonogenic survival under genotoxic pressure. RAD51 focus formation assays evaluate homologous recombination capacity, and cell cycle analysis monitors checkpoint responses. This tool empowers investigations into DNA damage signaling, PARP inhibitor sensitivity, and drug resistance in lung adenocarcinoma. For further technical inquiries, please contact Ascent Research.
